comprehensive -WSS

comprehensive

author：focus 2025-09-28 00:50:43 - browse：6186

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Roivant's CEO is a star, but biotech's black hole persists

entertainment

WSS

Bill would stop addiction treatment from triggering child abuse inquiry

The future of health care in the House

What to expect at HLTH 2023, the health care industry conference

3 questions for the future of Biden's cancer moonshot

Histogen: Failed biotech offers rare public look inside

Readout LOUD podcast: Live from the 2023 STAT Summit

Wikipedia

comprehensive

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Roche drug slashes death risk in early

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CZI to create biohub to build anti

New air purifier tech could be key to improving indoor air quality

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Novavax promises a turnaround & Lilly roils the obesity market

Histogen: Failed biotech offers rare public look inside

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Smaller biotechs seek to piggyback on weight loss drug boom

explore

Why age limits for politicians are a terrible idea

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: How researchers deal with rejection

STAT Summit: Ending the crisis of Black deaths in the U.S.

AI can decode, harness the power of the humane immune system

Roche drug slashes death risk in early

leisure time

entertainment

hotspot

knowledge